Sino Biopharmaceutical Limited

SEHK:1177 Stock Report

Market Cap: HK$79.1b

Sino Biopharmaceutical Dividends and Buybacks

Dividend criteria checks 3/6

Sino Biopharmaceutical is a dividend paying company with a current yield of 1.81% that is well covered by earnings. Next payment date is on 10th July, 2025 with an ex-dividend date of 16th June, 2025.

Key information

1.8%

Dividend yield

1.7%

Buyback Yield

Total Shareholder Yield3.5%
Future Dividend Yield1.8%
Dividend Growth15.5%
Next dividend pay date10 Jul 25
Ex dividend date16 Jun 25
Dividend per sharen/a
Payout ratio62%

Recent dividend and buyback updates

Recent updates

Sino Biopharmaceutical (HKG:1177) Is Increasing Its Dividend To CN¥0.04

May 23
Sino Biopharmaceutical (HKG:1177) Is Increasing Its Dividend To CN¥0.04

Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising

May 06
Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising

Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year

Apr 30
Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Apr 27
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Apr 06
Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Mar 23
Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult

Jan 13
Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Dec 08
Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Upcoming Dividend Payment

TodayMay 30 2025Ex Dividend DateJun 16 2025Dividend Pay DateJul 10 202524 days from Ex DividendBuy in the next 17 days to receive the upcoming dividend

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: 1177's dividend payments have been volatile in the past 10 years.

Growing Dividend: 1177's dividend payments have increased over the past 10 years.


Dividend Yield vs Market

Sino Biopharmaceutical Dividend Yield vs Market
How does 1177 dividend yield compare to the market?
SegmentDividend Yield
Company (1177)1.8%
Market Bottom 25% (HK)2.9%
Market Top 25% (HK)7.7%
Industry Average (Pharmaceuticals)2.5%
Analyst forecast (1177) (up to 3 years)1.8%

Notable Dividend: 1177's dividend (1.81%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.97%).

High Dividend: 1177's dividend (1.81%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.69%).


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (62.2%), 1177's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (25.1%), 1177's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/29 00:37
End of Day Share Price 2025/05/29 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sino Biopharmaceutical Limited is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Justin LiuBNP Paribas Securities (Asia)
Sharon ShiBOCI Research Ltd.